WHO panel recommends Eli Lilly Baricitinib, GSK-Vir Biotechnology drug for COVID treatment Ruchika Sharma14 Jan 2022 3:59 PM ISTNew Delhi: The World Health Organization on Friday gave a nod to two new drugs for the treatment of COVID-19 patients with severe and non-severe...
USFDA Warning: Risk of dental problems with Buprenorphine use Ruchika Sharma13 Jan 2022 4:02 PM ISTNew Delhi: The U.S. health regulator on Wednesday warned patients and prescribers about the risk of potential dental problems arising from the use of...
DCGI directs strict vigil on spurious Tocilizumab Injs distribution in India Medical Dialogues Team12 Jan 2022 5:13 PM ISTNew Delhi: Raising a safety alert, the Drugs Controller General of India, Central Drugs Standard Control Organisation (CDSCO) has directed all...
Biocon, Viatris application for Insulin Aspart rejected by USFDA Ruchika Sharma11 Jan 2022 3:30 PM ISTNew Delhi: Biocon Biologics, a subsidiary of biotechnology major Biocon, on Friday said the US health regulator has not approved an application for...
Anti COVID pill Avifavir (Favipiravir) effective against Omicron, Delta, says Russian firm MD Bureau10 Jan 2022 2:40 PM ISTNew Delhi: Russia-based pharma company ChemRar Group on Tuesday announced that its anti-Covid pill, named Avifavir (Favipiravir), is effective against...
Novartis gets CDSCO panel nod to study Alpelisib for early (prophylactic) and sustained improvement of hyperglycemia Medical Dialogues Team9 Jan 2022 8:45 PM ISTNew Delhi: Pharmaceutical major Novartis has got a conditional nod from the Subject Expert Committee (SEC) of the Central Drugs Standard Control...
Novartis gets CDSCO panel nod to study Ligelizumab in treatment of chronic inducible urticaria Medical Dialogues Team7 Jan 2022 2:21 PM ISTNew Delhi: Pharma major Novartis has got a go ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control...
Molnupiravir has major safety concerns, hence not part of National Protocol: ICMR chief Balram Bhargava Medical Dialogues Bureau6 Jan 2022 11:44 AM ISTNew Delhi: Pointing out to some major saftey concerns including teratogenicity, mutagenicity and also potential to cause cartilage damage and muscle...
Dr Reddys to launch anti-COVID drug Molnupiravir under brand name Molflu at Rs 35 per capsule Medical Dialogues Bureau5 Jan 2022 3:53 PM IST"Molflu (Molnupiravir) is expected to be available from early next week in pharmacies throughout the country with particular focus on states with high...
IPC flags adverse reaction linked to popular COVID drug Remdesivir Medical Dialogues Team4 Jan 2022 6:55 PM ISTNew Delhi: The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of December, has revealed that...
Takeda Pharma gets CDSCO panel nod to market Vadolizumab for subcutaneous route Medical Dialogues Team2 Jan 2022 11:30 AM ISTNew Delhi: Takeda Pharmaceuticals has got the go ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control...
13 pharma majors to launch anti-COVID drug Molnupiravir Medical Dialogues Team1 Jan 2022 7:36 PM ISTNew Delhi: Thirteen Indian pharmaceutical companies, including Torrent, Cipla, Sun Pharma, Dr Reddy's, Natco, Mylan, Hetero, Optimus will be...
